Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ...

The standard of care for newly diagnosed hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative metastatic breast cancer is typically endocrine therapy in combination ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window or on the link below. ASCO Rapid Recommendations Updates ...

One of the most important developments in breast cancer, especially for people with hormone receptor-positive (HR+) advanced breast cancer, is the discovery and treatment of ESR1 mutations. These ...

Recent recommendations — which were discussed at the CURE® Educated Patient® Breast Cancer Summit — addressed changes in both genetic and genomic testing in breast cancer. Patients with metastatic ...

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said. Metastatic breast cancer ...

Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. Experts ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor ...

First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...